Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Amortization - Deferred ChargesCost of RevenueDepreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Verastem (VSTM) Preferred Shares Issued (2011 - 2023)

Verastem's quarterly Preferred Shares Issued came in at $28.1 million in Q1 2023, up 38.77% quarter-over-quarter from $20.2 million in Q4 2011.

Verastem has reported Preferred Shares Issued for 2 years, with the latest figure at $28.1 million in Q1 2023.

  • For the quarter ending Q1 2023, Preferred Shares Issued changed N/A year-over-year to $28.1 million; the trailing twelve-month figure through Dec 2023 stood at $28.1 million (changed N/A YoY), and the FY2023 full-year result was $28.1 million, changed N/A from the prior year.
  • Preferred Shares Issued for Q1 2023 stood at $28.1 million, up from $20.2 million in the prior quarter.
  • The five-year high for Preferred Shares Issued was $28.1 million in Q1 2023, with the low at $28.1 million in Q1 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Shares Issued (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn -
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn -
10 Verastem 425.60 Mn 243.93 Mn 15.90 Mn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2023 28.10 Mn
Mar 31, 2023 28.10 Mn
Dec 31, 2011 20.25 Mn
Dec 31, 2011 20.25 Mn
Sep 30, 2011 31.94 Mn
Sep 30, 2011 31.94 Mn